These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
366 related articles for article (PubMed ID: 23611770)
1. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2. Wang W; Lv D; Qiu N; Zhang L; Hu C; Hu Y Bioorg Med Chem; 2013 Jun; 21(11):2886-94. PubMed ID: 23611770 [TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 1. Wang W; Shangguan S; Qiu N; Hu C; Zhang L; Hu Y Bioorg Med Chem; 2013 Jun; 21(11):2879-85. PubMed ID: 23601819 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors. Hu C; Li X; Wang W; Zhang L; Tao L; Dong X; Sheng R; Yang B; Hu Y Bioorg Med Chem; 2011 Sep; 19(18):5454-61. PubMed ID: 21855354 [TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship and antitumor activity of thio-benzodiazepines as p53-MDM2 protein-protein interaction inhibitors. Guo Z; Zhuang C; Zhu L; Zhang Y; Yao J; Dong G; Wang S; Liu Y; Chen H; Sheng C; Miao Z; Zhang W Eur J Med Chem; 2012 Oct; 56():10-6. PubMed ID: 22940704 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and CoMFA studies of N1-amino acid substituted 2,4,5-triphenyl imidazoline derivatives as p53-MDM2 binding inhibitors. Hu C; Dou X; Wu Y; Zhang L; Hu Y Bioorg Med Chem; 2012 Feb; 20(4):1417-24. PubMed ID: 22273545 [TBL] [Abstract][Full Text] [Related]
6. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction. Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248 [TBL] [Abstract][Full Text] [Related]
7. One-pot synthesis of spiro(indoline-3,4'-pyrazolo[3,4-b]pyridine)-5'-carbonitriles as p53-MDM2 interaction inhibitors. Ibrahim HS; Eldehna WM; Fallacara AL; Ahmed ER; Ghabbour HA; Elaasser MM; Botta M; Abou-Seri SM; Abdel-Aziz HA Future Med Chem; 2018 Dec; 10(24):2771-2789. PubMed ID: 30526032 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction. Zhuang C; Miao Z; Zhu L; Zhang Y; Guo Z; Yao J; Dong G; Wang S; Liu Y; Chen H; Sheng C; Zhang W Eur J Med Chem; 2011 Nov; 46(11):5654-61. PubMed ID: 21996465 [TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, and Alimujiang Y; Maimaiti A; Ablise M; Yang Z; Liu Z; Wang Y; Mutalipu Z; Yan T Anticancer Agents Med Chem; 2024; 24(6):423-435. PubMed ID: 38204258 [TBL] [Abstract][Full Text] [Related]
10. Discovery of 1-arylpyrrolidone derivatives as potent p53-MDM2 inhibitors based on molecule fusing strategy. Li J; Wu Y; Guo Z; Zhuang C; Yao J; Dong G; Yu Z; Min X; Wang S; Liu Y; Wu S; Zhu S; Sheng C; Miao Z; Zhang W Bioorg Med Chem Lett; 2014 Jun; 24(12):2648-50. PubMed ID: 24813735 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction. Zheng GH; Shen JJ; Zhan YC; Yi H; Xue ST; Wang Z; Ji XY; Li ZR Eur J Med Chem; 2014 Jun; 81():277-88. PubMed ID: 24852275 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel antitumor spirotetrahydrothiopyran-oxindole derivatives as potent p53-MDM2 inhibitors. Ji C; Wang S; Chen S; He S; Jiang Y; Miao Z; Li J; Sheng C Bioorg Med Chem; 2017 Oct; 25(20):5268-5277. PubMed ID: 28797774 [TBL] [Abstract][Full Text] [Related]
13. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors. Si D; Luo H; Zhang X; Yang K; Wen H; Li W; Liu J Bioorg Chem; 2021 Oct; 115():105268. PubMed ID: 34426149 [TBL] [Abstract][Full Text] [Related]
15. Identification of new inhibitors of Mdm2-p53 interaction via pharmacophore and structure-based virtual screening. Atatreh N; Ghattas MA; Bardaweel SK; Rawashdeh SA; Sorkhy MA Drug Des Devel Ther; 2018; 12():3741-3752. PubMed ID: 30464405 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of novel orally active p53-MDM2 interaction inhibitors. Miyazaki M; Naito H; Sugimoto Y; Yoshida K; Kawato H; Okayama T; Shimizu H; Miyazaki M; Kitagawa M; Seki T; Fukutake S; Shiose Y; Aonuma M; Soga T Bioorg Med Chem; 2013 Jul; 21(14):4319-31. PubMed ID: 23685175 [TBL] [Abstract][Full Text] [Related]
17. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. Ding K; Lu Y; Nikolovska-Coleska Z; Wang G; Qiu S; Shangary S; Gao W; Qin D; Stuckey J; Krajewski K; Roller PP; Wang S J Med Chem; 2006 Jun; 49(12):3432-5. PubMed ID: 16759082 [TBL] [Abstract][Full Text] [Related]